Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Dejun Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6933-2666; OpenAlex author ID A5100667738. Sources: OpenAlex.

Their work

Papers
27 (first author 2, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
61
Papers, trials and grants by year

2014: 1 paper · 2015: 5 papers · 2016: 1 paper · 2017: 2 papers · 2018: none · 2019: 2 papers · 2020: 2 papers · 2021: 5 papers · 2022: 5 papers · 2023: 3 papers · 2024: 1 paper

Papers 27

  1. Oncogenic GALNT5 confers FOLFIRINOX resistance via activating the MYH9/ NOTCH/ DDR axis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41419-024-07110-w↗
  2. The genomic, transcriptomic, and immunological profiles of perineural invasion in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s11427-022-2146-5↗
  3. Immunosuppression, immune escape, and immunotherapy in pancreatic cancer: focused on the tumor microenvironment. Co-author DOI 10.1007/s13402-022-00741-1↗
  4. ADAMTS12 promotes migration and epithelial-mesenchymal transition and predicts poor prognosis for pancreatic cancer. Co-author DOI 10.1016/j.hbpd.2022.04.005↗
  5. IRAK2-NF-κB signaling promotes glycolysis-dependent tumor growth in pancreatic cancer. First author DOI 10.1007/s13402-022-00670-z↗
  6. SULF2 enhances GDF15-SMAD axis to facilitate the initiation and progression of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2022.215693↗
  7. Modeling of cancer-related body-wide effects identifies LTB4 as a diagnostic biomarker for pancreatic cancer. First author DOI 10.1016/j.ebiom.2022.104050↗
  8. Increased SPON1 promotes pancreatic ductal adenocarcinoma progression by enhancing IL-6 trans-signalling. Co-author DOI 10.1111/cpr.13237↗
  9. Exploitation and Verification of a Stroma- and Metastasis-Associated Risk Prognostic Signature in Pancreatic Adenocarcinoma. Co-author DOI 10.3390/ph15111336↗
  10. CD74 promotes perineural invasion of cancer cells and mediates neuroplasticity via the AKT/EGR-1/GDNF axis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2021.03.016↗
  11. Single-cell RNA sequencing reveals that targeting HSP90 suppresses PDAC progression by restraining mitochondrial bioenergetics. Co-author DOI 10.1038/s41389-021-00311-4↗
  12. Identification of a subset of immunosuppressive P2RX1-negative neutrophils in pancreatic cancer liver metastasis. Co-author DOI 10.1038/s41467-020-20447-y↗
  13. Integrated genomic and transcriptomic analysis reveals unique characteristics of hepatic metastases and pro-metastatic role of complement C1q in pancreatic duc… Co-author DOI 10.1186/s13059-020-02222-w↗
  14. TRIM50 Suppresses Pancreatic Cancer Progression and Reverses the Epithelial-Mesenchymal Transition via Facilitating the Ubiquitous Degradation of Snail1. Last author DOI 10.3389/fonc.2021.695740↗
  15. Perineural Invasion Reprograms the Immune Microenvironment through Cholinergic Signaling in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-19-2689↗
  16. Molecular markers associated with perineural invasion in pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/ol.2020.11866↗
  17. DKK2 Impairs Tumor Immunity Infiltration and Correlates with Poor Prognosis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1155/2019/8656282↗
  18. SFRP4 is a prognostic marker and correlated with Treg cell infiltration in pancreatic ductal adenocarcinoma. Last author PMID 30906634↗
  19. The role of Dickkopf-1 as a potential prognostic marker in pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/15384101.2017.1356510↗
  20. High Expression of FAM83B Predicts Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma and Correlates with Cell Cycle and Cell Proliferation. Co-author DOI 10.7150/jca.20086↗
  21. Efficacy of Neo-Adjuvant Chemoradiotherapy for Resectable Pancreatic Adenocarcinoma: A PRISMA-Compliant Meta-Analysis and Systematic Review. Co-author DOI 10.1097/md.0000000000003009↗
  22. Decreased LKB1 predicts poor prognosis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1038/srep10575↗
  23. Corrigendum: Decreased LKB1 predicts poor prognosis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1038/srep15869↗
  24. High expression of DDR1 is associated with the poor prognosis in Chinese patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-015-0202-1↗
  25. Downregulation of RPL15 may predict poor survival and associate with tumor progression in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.5939↗
  26. High expression of WISP-1 correlates with poor prognosis in pancreatic ductal adenocarcinoma. Co-author PMID 26550461↗
  27. Effect of CD74 on the prognosis of patients with resectable pancreatic cancer. Co-author DOI 10.1016/s1499-3872(14)60011-4↗

Closest collaborators

The 25 strongest of 61 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yongwei Sun · 25 shared papers, 2014–2024 · strength 2.54
  2. Yan‐Miao Huo · 21 shared papers, 2014–2024 · strength 2.04
  3. Minwei Yang · 17 shared papers, 2015–2024 · strength 1.75
  4. Rong Hua · 18 shared papers, 2014–2024 · strength 1.59
  5. Jian‐Yu Yang · 17 shared papers, 2015–2022 · strength 1.52
  6. Xueliang Fu · 15 shared papers, 2015–2024 · strength 1.41
  7. Shu‐Heng Jiang · 10 shared papers, 2015–2023 · strength 1.13
  8. Hong‐Fei Yao · 6 shared papers, 2022–2024 · strength 0.94
  9. Zhigang Zhang · 9 shared papers, 2015–2023 · strength 0.90
  10. Jia-Hao Zheng · 5 shared papers, 2022–2024 · strength 0.81
  11. Junfeng Zhang · 8 shared papers, 2016–2023 · strength 0.77
  12. Ruizhe He · 5 shared papers, 2019–2023 · strength 0.60
  13. Wei Chiang Liu · 6 shared papers, 2016–2022 · strength 0.59
  14. Li-Peng Hu · 5 shared papers, 2020–2022 · strength 0.58
  15. Zong‐Hao Duan · 3 shared papers, 2022–2024 · strength 0.49
  16. Qin-Yuan Jia · 3 shared papers, 2022–2024 · strength 0.49
  17. Dapeng Xu · 3 shared papers, 2022–2023 · strength 0.45
  18. Jian Yang · 3 shared papers, 2022 · strength 0.39
  19. Xu Wang · 3 shared papers, 2021–2023 · strength 0.36
  20. Qin Yang · 3 shared papers, 2021–2023 · strength 0.36
  21. Shan Zhang · 2 shared papers, 2022–2023 · strength 0.33
  22. Ping Lu · 3 shared papers, 2020–2022 · strength 0.32
  23. Rongkun Li · 2 shared papers, 2021–2023 · strength 0.32
  24. Yu-Heng Zhu · 2 shared papers, 2022–2023 · strength 0.31
  25. Jing Xue · 3 shared papers, 2020–2022 · strength 0.31

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.